TR201819805T4 - Flavaglin türevleri̇. - Google Patents

Flavaglin türevleri̇. Download PDF

Info

Publication number
TR201819805T4
TR201819805T4 TR2018/19805T TR201819805T TR201819805T4 TR 201819805 T4 TR201819805 T4 TR 201819805T4 TR 2018/19805 T TR2018/19805 T TR 2018/19805T TR 201819805 T TR201819805 T TR 201819805T TR 201819805 T4 TR201819805 T4 TR 201819805T4
Authority
TR
Turkey
Prior art keywords
flavaglin
derivatives
enantiomers
relates
solvates
Prior art date
Application number
TR2018/19805T
Other languages
English (en)
Inventor
Marion Frederic
Bachir Kaloun El
Lieby-Muller Frederic
Perez Michel
Annereau Jean-Philippe
Creancier Laurent
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of TR201819805T4 publication Critical patent/TR201819805T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)

Abstract

Buluş özellikle bir ilaç olarak, daha özellikle de kanser tedavisinde kullanım için enantiyomerlerinden biri veya enantiyomerlerinin bir karışımı formunda genel formül (I)'e sahip bileşikler ve bunların farmasötik olarak kabul edilebilir tuzları ve/veya solvatları ile ilgilidir. Buluş aynı zamanda bunları içeren farmasötik bileşimler ve bunların üretim yöntemleri ile ilgilidir.
TR2018/19805T 2014-07-04 2015-07-06 Flavaglin türevleri̇. TR201819805T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1456474A FR3023290B1 (fr) 2014-07-04 2014-07-04 Derives de flavaglines

Publications (1)

Publication Number Publication Date
TR201819805T4 true TR201819805T4 (tr) 2019-01-21

Family

ID=52016681

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/19805T TR201819805T4 (tr) 2014-07-04 2015-07-06 Flavaglin türevleri̇.

Country Status (9)

Country Link
US (2) US10047064B2 (tr)
EP (3) EP3164393B1 (tr)
JP (4) JP6637954B2 (tr)
DK (2) DK3418273T3 (tr)
ES (2) ES2908225T3 (tr)
FR (1) FR3023290B1 (tr)
PL (2) PL3164393T3 (tr)
TR (1) TR201819805T4 (tr)
WO (1) WO2016001441A1 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2870037T3 (es) 2015-11-25 2021-10-26 Effector Therapeutics Inc Compuestos inhibidores de EIF4-A y métodos relacionados con los mismos
EA037781B1 (ru) * 2017-06-19 2021-05-20 Фьючеркем Ко., Лтд. 18f-меченое соединение для диагностики рака предстательной железы и его применение
EP3755693B1 (en) * 2018-02-19 2024-06-12 Memorial Sloan-Kettering Cancer Center Agents and methods for treating dysproliferative diseases
US20210346337A1 (en) * 2018-10-09 2021-11-11 The Research Institute At Nationwide Children's Hospital Anticancer rocaglamide derivatives
US11427595B2 (en) * 2018-10-22 2022-08-30 Trustees Of Boston University Compositions and methods for inhibiting viral infection
KR20220080139A (ko) 2019-10-10 2022-06-14 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ866500A0 (en) * 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods
DE102004024504A1 (de) * 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
CA2652873A1 (en) * 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
EP2189453A1 (en) * 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
AU2009321723A1 (en) * 2008-12-05 2010-06-10 Intermed Discovery Gmbh Inhibitors of HIF-1 protein accumulation

Also Published As

Publication number Publication date
JP6637954B2 (ja) 2020-01-29
EP3998257A1 (fr) 2022-05-18
FR3023290B1 (fr) 2016-08-19
JP2023159393A (ja) 2023-10-31
ES2908225T3 (es) 2022-04-28
JP2020063289A (ja) 2020-04-23
DK3418273T3 (da) 2022-03-21
PL3164393T3 (pl) 2019-03-29
DK3164393T3 (en) 2019-01-21
JP2022000455A (ja) 2022-01-04
EP3418273A1 (fr) 2018-12-26
JP6951406B2 (ja) 2021-10-20
US20180086729A1 (en) 2018-03-29
JP2017519796A (ja) 2017-07-20
WO2016001441A1 (fr) 2016-01-07
US10047064B2 (en) 2018-08-14
EP3164393A1 (fr) 2017-05-10
PL3418273T3 (pl) 2022-08-01
US20170137400A1 (en) 2017-05-18
ES2700156T3 (es) 2019-02-14
JP7340574B2 (ja) 2023-09-07
EP3418273B1 (fr) 2022-01-12
EP3164393B1 (fr) 2018-09-19
US10519125B2 (en) 2019-12-31
FR3023290A1 (fr) 2016-01-08

Similar Documents

Publication Publication Date Title
PH12017501191B1 (en) Quinazoline derivatives used to treat hiv
PH12016501440A1 (en) Novel heterocyclic compounds
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
TW201613864A (en) Novel compounds
TR201819805T4 (tr) Flavaglin türevleri̇.
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
PH12016501997B1 (en) Cycloalkyl-linked diheterocycle derivatives
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases